With results being published on phase three trials of new therapeutics for hepatocellular carcinoma (HCC), now is the appropriate time for AASLD members to look at these new therapies as well as review how to enhance trial design to better assess the efficacy of these new therapies. Registration is open for a conference that will provide this in-depth look at both therapeutics and trial design.
Emerging Topic Conference: Advances in HCC Therapies and Trial Design will take place in Atlanta, Ga. on March 22-23. Program chairs Josep M. Llovet, MD, FAASLD, and Lewis R. Roberts, MBChB, PhD, FAASLD, encourage physicians, researchers, nurse practitioners and physician assistants as well as industry personnel from pharmaceutical companies and biotechs to join them for the robust two-day program outlining the latest precision therapies and looking for ways to improve trial design.
“In the management of HCC during the last two years, there has been a revolution,” said Dr. Llovet. “We had only one therapy available: sorafenib, and now several positive phase III trials change the landscape of molecular target therapies for this very difficult to treat cancer.”
Dr. Llovet and Dr. Roberts have put together a program that dives into the new advancements in molecular understanding and presentation of HCC, biomarkers of HCC and in the management of the disease with the new drugs, including lenvatinib for the front line and regorafenib, cabozantinib and ramucirumab in second line.
“So the insights of all these trials is to understand which patients can benefit from which drugs,” said Dr. Llovet. “There is a lot of interest in understanding immunotherapy in HCC to see why some patients respond so well. Also, as a result of all the new data that we have in adjuvant with several trials negative, also an intermediate with several trials with combination therapies that have been negative, it’s the time to revisit how we should design clinical trials now to capture the benefit of new drugs.”
Dr. Llovet also noted that attendees will be exposed to other concepts, such as new data on a liquid biopsy and new immune approaches such as the role of CAR-T cells or oncolytic viruses in HCC.
Another benefit of the Emerging Topics Conference is the opportunity to network with not only other physicians managing patients with HCC and researchers looking at new therapeutics, but also the opportunity to interact with key opinion leaders and the expert presenters.
“The new AASLD guidance on management of HCC also will be analyzed in the setting of this meeting and there will be a specific lecture devoted to that,” Dr. Llovet added. “There will be a lot of opportunities to understand the new guidelines of AASLD.”